The LANCE® Ultra Human PD-L1 Detection Kit is designed for detection and quantitation of human PD-L1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
true falseYou successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
The LANCE® Ultra Human PD-L1 Detection Kit is designed for detection and quantitation of human PD-L1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Programmed death ligand 1 (PDL-1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PDL-1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PDL-1, together with PDL-2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PDL-1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cellcycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PDL-1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
| Assay Target | PD-L1 |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Experimental Type | In vitro |
| Product Brand Name | LANCE Ultra |
| Shipping Condition | Blue Ice |
| Target Species | Human |
| Therapeutic Area | Cancer |
| Unit Size | 500 Assay Points |
Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.
